Cardiff Oncology shareholders approve increase in shares under 2021 equity plan to 8.15M

Cardiff Oncology, Inc.

All seven director nominees elected: For votes ranged 15.2M–15.5M; no director received >601K abstentions.
Ratification of BDO USA as auditor for FY2024 approved: 27.1M For, 0.26M Against, 0.33M Abstain.
Amendment to 2021 Equity Incentive Plan increasing authorized shares to 8,150,000 approved: 13.1M For, 2.4M Against, 0.35M Abstain.
Advisory vote on executive compensation passed: 13.3M For, 2.1M Against, 0.41M Abstain.
All proposals passed; broker non-votes noted for director election, equity plan, and say-on-pay.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.